Publications by authors named "Joshua Kantrowitz"

Claim this Profile
E
Effect Size Deflation With Increasing Sample Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action.
Joshua T Kantrowitz, Megan R Mayer, Tse-Hwei Choo, Kevin Liu, Viraj Govani

Am J Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study.
Haig Goenjian, Abhishek Pratap, Cassandra Snipes, Brendan D Hare, Joshua T Kantrowitz

Schizophrenia (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Receptor Agonist Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia.
Francesca L Ricciardi, Jayda L Melnitsky, Shannon B Peleg, Preetika Govil, Joshua T Kantrowitz

J Clin Psychiatry· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the inter-rater reliability of the Schizophrenia Cognition Rating Scale: a non-interventional quantitative study.
Sebastien Tulliez, Stella Karantzoulis, James C Marcus, Montserrat Casamayor, Cassie Blanchard, Joshua T Kantrowitz

Schizophrenia (Heidelb)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.
Clara Fonteneau, Zailyn Tamayo, Ally Price, Lining Pan, Yvette Afriyie-Agyemang, Joshua T Kantrowitz

medRxiv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.
Preetika Govil, Joshua T Kantrowitz

CNS Drugs· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.
Pejman Sehatpour, Joshua T Kantrowitz

Biol Psychiatry· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research.
Joohyun Yoon, Megan R Mayer, Tala Berro, Stephanie Brazis, Joshua T Kantrowitz

Pharmaceut Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry.
Joshua T Kantrowitz, Daniel C Javitt

Adv Neurobiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tardive Dyskinesia Suppressed With Ginkgo Biloba.
Petros D Petridis, Ari B Jaffe, Joshua T Kantrowitz, Jack Grinband

J Clin Psychopharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
Viraj Govani, Adithya M Shastry, Dan V Iosifescu, Preetika Govil, Megan R Mayer, Joshua T Kantrowitz

Schizophr Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Illness Phase as a Key Assessment and Intervention Window for Psychosis.
Christian G Kohler, Daniel H Wolf, Anissa Abi-Dargham, Alan Anticevic, Youngsun T Cho, Joshua T Kantrowitz

Biol Psychiatry Glob Open Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.
Pejman Sehatpour, Dan V Iosifescu, Heloise M De Baun, Constance Shope, Megan R Mayer, Joshua T Kantrowitz

Biol Psychiatry· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early auditory processing dysfunction in schizophrenia: Mechanisms and implications.
Clément Dondé, Joshua T Kantrowitz, Alice Medalia, Alice M Saperstein, Andrea Balla

Neurosci Biobehav Rev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Developments in the Treatment of Schizophrenia: An Expert Roundtable.
Joshua T Kantrowitz, Christoph U Correll, Rakesh Jain, Andrew J Cutler

Int J Neuropsychopharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
Viraj Govani, Adithya Shastry, Daniel Iosifescu, Preetika Govil, Megan Mayer, Joshua Kantrowitz

Res Sq· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Ondine Adam, Martin Blay, Andre R Brunoni, Hsin-An Chang, July S Gomes, Joshua T Kantrowitz

Schizophr Bull· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting.
Elizabeth Deckler, Melissa Ferland, Stephanie Brazis, Megan R Mayer, Marlene Carlson, Joshua T Kantrowitz

Int J Neuropsychopharmacol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the reproducibility of proton magnetic resonance spectroscopy brain thermometry: Theoretical and empirical approaches.
Zhengchao Dong, Joshua T Kantrowitz, J John Mann

NMR Biomed· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additional perspective on cariprazine and negative symptoms.
Joshua T Kantrowitz

Expert Opin Pharmacother· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease.
Daniel C Javitt, Joshua T Kantrowitz

Schizophr Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
Pejman Sehatpour, Daniel C Javitt, Heloise M De Baun, Marlene Carlson, Anna Beloborodova, Joshua T Kantrowitz

Neuropsychopharmacology· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.
Anissa Abi-Dargham, Jonathan A Javitch, Mark Slifstein, Alan Anticevic, Monica E Calkins, Joshua Kantrowitz

Schizophr Bull· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.
Joshua T Kantrowitz

CNS Drugs· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
D-Serine: A Cross Species Review of Safety.
Amir Meftah, Hiroshi Hasegawa, Joshua T Kantrowitz

Front Psychiatry· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis